GHRP-2vsTesamorelin

GHRP-2 (Growth Hormone Releasing Peptide-2) is a synthetic hexapeptide that binds to the GHS-R1a receptor on pituitary somatotrophs with high affinity, making it the second most potent GHRP for GH release after hexarelin. It activates the canonical Gq/11-PLC-IP3-calcium pathway, triggering robust GH vesicle exocytosis.

Beyond direct pituitary action, GHRP-2 modulates GH release at the hypothalamic level through two complementary mechanisms. It stimulates GHRH-producing neurons in the arcuate nucleus, amplifying the endogenous GHRH signal, and simultaneously suppresses somatostatin release from periventricular neurons, removing the inhibitory brake on GH secretion. This dual hypothalamic action explains why combining GHRP-2 with a GHRH analogue produces synergistic rather than merely additive GH release — the GHRP removes somatostatin inhibition while the GHRH analogue directly activates somatotrophs.

GHRP-2 occupies a middle ground in the GHRP family regarding selectivity. It produces moderate cortisol and prolactin elevation — less than hexarelin but more than ipamorelin. Its ghrelin-mimetic activity also stimulates appetite through hypothalamic NPY/AgRP neurons, though this effect is less pronounced than GHRP-6. Some research suggests GHRP-2 may have gastroprotective properties, with studies showing protection against ethanol-induced gastric mucosal damage in animal models. The peptide has been most extensively studied in Japan, where clinical trials evaluated its potential for treating GH deficiency, and it remains one of the best-characterized GHRPs in terms of pharmacology and dose-response relationships.

Tesamorelin is a synthetic GHRH analogue consisting of all 44 amino acids of human GHRH with a trans-3-hexenoic acid group attached to the tyrosine at position 1. This lipophilic modification enhances receptor binding affinity and provides modest resistance to dipeptidyl peptidase-IV (DPP-IV) cleavage, improving its pharmacokinetic profile compared to native GHRH.

Like other GHRH analogues, tesamorelin activates the GHRH receptor on pituitary somatotrophs via the Gs/cAMP/PKA pathway, stimulating endogenous GH synthesis and pulsatile secretion. The resulting increase in circulating GH and IGF-1 produces its primary therapeutic effect: targeted reduction of visceral adipose tissue (VAT). GH-mediated lipolysis is particularly active in visceral fat depots because these adipocytes have the highest density of GH receptors and are most responsive to GH-stimulated hormone-sensitive lipase activation.

The specificity of tesamorelin's effect on visceral rather than subcutaneous fat has been well-documented in clinical trials. Visceral adipose tissue is metabolically distinct — it drains directly into the portal circulation and contributes disproportionately to hepatic insulin resistance, inflammatory cytokine production, and cardiovascular risk. By selectively reducing this depot, tesamorelin improves the cardiometabolic profile beyond what would be expected from total fat loss alone. Clinical trials also showed improvements in hepatic steatosis (fatty liver) markers, triglyceride levels, and trunk fat distribution. It remains the only GHRH analogue with active FDA approval, specifically for HIV-associated lipodystrophy, where visceral fat accumulation is a common and distressing side effect of antiretroviral therapy.